Synjardy® (empagliflozin/metformin) for Type 2 Diabetes Control

What Synjardy® Is and How It Works

Synjardy is a prescription tablet that combines empagliflozin (an SGLT2 inhibitor) and metformin (a biguanide). It is used in adults with type 2 diabetes, alongside diet and exercise, to improve blood glucose control. Tablets are available as immediate‑release (twice daily) and Synjardy XR (extended‑release, once daily). You can check Synjardy price and strengths before ordering. If needed, compare Synjardy cost without insurance on this page.

CanadianInsulin is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies. We partner with vetted pharmacies to supply authentic brand medications with a broad selection and value‑focused pricing.

Empagliflozin helps the kidneys remove excess glucose by blocking sodium‑glucose cotransporter 2 (SGLT2). Metformin reduces liver glucose production and improves insulin sensitivity. The combination targets complementary pathways, which can support A1C reduction, modest weight loss, and gentle blood pressure lowering.

Synjardy may also be prescribed when the empagliflozin component is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. It is not for type 1 diabetes or for treatment of diabetic ketoacidosis.

Dosage and Usage

• Form and cadence: Synjardy immediate‑release is taken twice daily with meals. Synjardy XR is taken once daily with the morning meal.
• Starting approach: Prescribers often begin with a lower metformin dose to reduce stomach upset and adjust the empagliflozin component based on prior therapy.
• Common strengths: Examples include 5 mg/1000 mg and 12.5 mg/1000 mg. XR options include 12.5 mg/1000 mg. Your total daily dose may be titrated toward empagliflozin 10–25 mg and metformin 1000–2000 mg, as tolerated.
• With meals: Take tablets with food to lessen gastrointestinal side effects. Swallow XR tablets whole; do not split, crush, or chew.
• Hydration: Maintain adequate fluid intake, as SGLT2 inhibitors increase urination and can cause volume depletion.
• Renal checks: Kidney function is typically assessed before starting and monitored during use. Dose adjustments or discontinuation may be needed if kidney function declines.
• Missed dose (IR): Take when remembered unless it is almost time for the next dose. Do not double the next dose.
• Missed dose (XR): Take the missed tablet the same day when remembered; skip if the next day is near. Do not take two XR tablets at once.
• Peri‑procedure: Metformin may be held before certain imaging procedures with iodinated contrast and before surgery, per clinical guidance.
• Concomitant agents: When combined with insulin or a sulfonylurea, prescribers may reduce those doses to lower hypoglycemia risk.

• Storage: Keep tablets at 20–25°C (68–77°F). Short excursions 15–30°C (59–86°F) are acceptable.
• Moisture control: Store in the original container with the desiccant. Keep the bottle tightly closed and away from humidity.
• Light and children: Protect from excessive heat and direct light. Keep out of reach of children and pets.
• Travel: Carry your medication in a cabin bag. Avoid hot cars. Pack extra doses and a copy of your prescription.
• No refrigeration: Do not freeze or refrigerate tablets.

Benefits and Savings

Synjardy simplifies therapy by combining two proven glucose‑lowering medicines in one tablet. The SGLT2 component can support modest weight reduction and small blood pressure decreases. In appropriate adults with cardiovascular disease, the empagliflozin component has demonstrated cardiovascular and kidney benefits. Many patients appreciate the convenience of once‑daily XR dosing.

Pricing varies by strength and form. Many customers save 60–80% vs typical U.S. prices, which can help when comparing Synjardy cost without insurance. See our promotions page for current offers, including any Synjardy coupon if available.

Side Effects and Safety

• Gastrointestinal: nausea, diarrhea, stomach upset, gas, abdominal discomfort, decreased appetite.
• Genitourinary: increased urination, urinary tract infections, genital yeast infections.
• General: thirst, headache, dizziness, fatigue.
• Circulatory: low blood pressure or dehydration, especially in older adults or those on diuretics.
• Metabolic: changes in kidney tests; low vitamin B12 with long‑term metformin.
• Skin: rash or itching.

Serious risks are uncommon but include lactic acidosis with metformin (higher risk with significant kidney impairment, age 65+, hypoxic states, liver disease, or heavy alcohol use). SGLT2‑related risks include ketoacidosis (which may occur with only moderate glucose elevation), severe urinary infections, rare necrotizing fasciitis of the perineum (Fournier’s gangrene), and volume depletion. Not for type 1 diabetes or active ketoacidosis. Hypoglycemia can occur when used with insulin or sulfonylureas; those doses may need adjustment by your prescriber.

Onset Time

Many people see fasting glucose improvements within the first week as therapy begins. Gastrointestinal tolerance to metformin often improves over 1–2 weeks as the dose is adjusted. A1C reductions typically emerge by weeks 2–4 and continue to improve over 12–24 weeks as the maintenance dose is reached.

Weight effects with the SGLT2 component are usually modest, often 2–3 kg over several months, and can vary. Small reductions in systolic blood pressure may appear by 4–8 weeks, especially in those with higher baseline values.

Compare With Alternatives

Some adults may consider a GLP‑1 receptor agonist alongside or instead of an SGLT2/biguanide combination, based on goals and tolerability. Oral semaglutide, branded as Rybelsus®, is a once‑daily tablet that can produce larger A1C and weight reductions but may cause more nausea early in treatment. Learn more about Rybelsus.

Once‑weekly injectable options include dulaglutide, branded as Trulicity®, and tirzepatide, branded as Mounjaro®. These agents often deliver strong glycemic and weight effects with convenient weekly dosing. See Trulicity for details. Your prescriber can help decide whether adding a GLP‑1/GIP agent, continuing metformin, or switching therapies aligns with your goals.

Combination Therapy

• Metformin base: Synjardy provides metformin within the same tablet, so separate metformin is usually not required.
• Basal insulin: Often combined when additional fasting control is needed; insulin doses may be reduced to limit hypoglycemia.
• GLP‑1 RA: Common add‑on for further A1C and weight benefits; start low to improve tolerability.
• DPP‑4 inhibitor: Less common when a GLP‑1 RA is planned; avoid duplicative mechanisms.
• Antihypertensives and statins: Continue as indicated for cardiovascular risk management.

Patient Suitability and Cost‑Saving Tips

Synjardy may suit adults with type 2 diabetes who need additional A1C reduction and prefer an oral option. It is not for type 1 diabetes or ketoacidosis. It is generally avoided in severe kidney impairment or dialysis, and used cautiously with a history of recurrent urinary or genital infections, dehydration, or heavy alcohol use. Discuss pregnancy, breastfeeding, and surgical plans with your care team.

To save on therapy, consider multi‑month orders if appropriate for your prescription. Choose the immediate‑release or XR version your prescriber recommends to match dosing needs and reduce waste. Ordering the exact strength specified can help avoid tablet splitting, especially since XR tablets must not be crushed or split. Set simple reminders to re‑order before you run out.

Authoritative Sources

Official Synjardy patient website (Boehringer Ingelheim and Lilly)

Health Canada Drug Product Database (search Synjardy)

FDA Drug Database (Drugs@FDA) search for Synjardy

Order Synjardy® from CanadianInsulin: add to cart, upload your prescription, and we ship with prompt, express, cold‑chain handling.

This page is educational and does not replace medical advice. Always consult your healthcare professional for diagnosis, treatment, and personalized dosing.